In the present study, we analyzed Programmed Death Ligand-1 (PD-L1) expression in radical cystectomy (RC) specimens from patients with muscle-invasive urothelial carcinoma (UC), in order to assess any correlations with specific clinicopathological features and its potential prognostic value. A multi-institutional study was performed within the departments of urology and pathology at the Mureș County Hospital, Romania, and Centre Hospitalier Lyon Sud, France. Sixty-nine patients with MIBC were included, for whom tumor histology (conventional versus histological variant/differentiation), tumor extension (T), lymph node involvement (N), and distant metastases (M) were recorded. PD-L1 immunostaining was performed using the 22C3 clone and was interpreted using the combined positive score (CPS) as recommended (Dako Agilent, Santa Clara, CA, USA). Positive PD-L1 immunostaining was more prevalent among UCs with squamous differentiation compared to conventional UCs and trended towards an improved OS (p = 0.366). We found the T stage to be a risk factor for poor survival in PD-L1-positive patients (HR 2.9, p = 0.021), along with the N stage in PD-L1-negative patients (HR 1.98, p = 0.007). No other clinicopathological factor was found to be significantly associated with PD-L1 positivity. Thus, we confirm the need for PD-L1 immunostaining prior to initiating immune checkpoint inhibitor therapy for a more accurate assessment of the patients’ chances of responding to treatment.

No abstract

No abstract

The aim of this study is to evaluate the efficacy and safety of Uractiv Control as an alternative treatment with no side effects in Overactive Bladder (OAB). We performed a prospective study over a period of 15 months (May 2018- September 2019) in Department of Urology from Targu-Mureș. We included 165 patients diagnosed with OAB wet (129 patients) and dry form (36 patients) which were fully evaluated over a 3-month period of treatment. 48 patients were treated with placebo 1 month and were evaluated by the same parameters like Uractiv Control group. The frequency of micturition during the day and night after the treatment with Uractiv Control was improved compared to placebo group (p=0.0001) and also the loss of urine episodes (p=0.03). Patients did not report any significant side effects of the treatment. Uractiv Control represents a safe treatment option with no side effects and improvement of the storage in OAB.

No abstract